Form 8K Voyager Therapeutics Inc For: 18 November By Investing.com
This article announces that Voyager Therapeutics Inc. filed a Form 8K on November 18, 2026. The filing is a standard disclosure for significant events that shareholders should know about. The stock symbol for Voyager Therapeutics is VYGR.
Form 8K Voyager Therapeutics Inc For: 18 November By Investing.com
This article reports on the filing of a Form 8K by Voyager Therapeutics Inc. on November 18. The stock symbol for Voyager Therapeutics Inc. is VYGR. The article indicates a 9.87% increase in VYGR's stock.
Voyager Therapeutics Issues Amendment to Correct EDGAR Submission Header for Q3 2026 Report
Voyager Therapeutics, Inc. submitted Amendment No. 1 to its current report on November 18, 2026, to correct a technical error in the original EDGAR filing header. The amendment rectifies the mistaken reference to Item 2.01, updating it to the accurate Items 2.02 and 9.01, without altering the original filing's content. The original report, filed on November 5, 2026, detailed the company's third-quarter 2026 financial results and corporate updates.
An investment manager reports a 3.87M-share stake in Voyager Therapeutics (VYGR).
Armistice Capital, LLC and its managing member, Steven Boyd, have reported a beneficial ownership of 3,872,000 common shares in Voyager Therapeutics, Inc. (VYGR), representing 1.26% of the class as of September 30, 2026. Both parties hold shared voting and dispositive power over these shares. Armistice Capital acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares, with Boyd beneficially owning them through his role as managing member.
Voyager Therapeutics Eyes Tau Antibody Data and Alzheimer’s Gene Therapy Dosing
Voyager Therapeutics expects a readout from its tau antibody study this quarter and plans to begin dosing patients in its Alzheimer's gene therapy program soon. CEO Al Sandrock highlighted these as part of a "catalyst-rich period" for the company, which also includes a collaboration with Neurocrine on a gene therapy for Friedreich's ataxia. The company's gene therapy for tau reduction, VY1706, has FDA clearance, and initial safety assessments are expected in the first quarter, with tau measurements in cerebrospinal fluid about a year after dosing starts.
VT6.HA Interactive Stock Chart | Voyager Therapeutics Inc. R Stock
The article provides an interactive stock chart for Voyager Therapeutics Inc. (VT6.HA), showing a delayed quote of EUR 1.4630, down 3.43% at the close on November 13. It includes options for various chart ranges and intervals, noting an "Oops, something went wrong" message.
Voyager Therapeutics, Inc. (VYGR) Stock Price, News, Quote & History
Voyager Therapeutics, Inc. (VYGR) closed at $1.70 on November 12, experiencing a -3.41% decrease. The biotechnology company focuses on developing gene therapies and anti-tau antibodies for neurological diseases like Alzheimer's and Huntington's, with a 1-year target estimate of $14.22 from analysts. Despite recent price declines, the company has several ongoing collaborations and a pipeline of therapeutic programs.
Quarterly loss narrows to $24.7M at Voyager Therapeutics (VYGR), while collaboration revenue falls.
Voyager Therapeutics (VYGR) reported a narrowed net loss of $24.7 million in Q3 2026, down from $27.9 million a year earlier, and a nine-month net loss of $77.1 million, also an improvement. However, collaboration revenue significantly decreased to $4.01 million for the quarter and $9.77 million for the first nine months. The company stated it has $132.1 million in cash, cash equivalents, and marketable securities, expected to fund operations for at least twelve months.
Voyager Therapeutics Inc earnings beat by $0.02, revenue fell short of estimates
Voyager Therapeutics Inc (NASDAQ: VYGR) reported third-quarter EPS of $-0.400, surpassing analyst estimates by $0.02, but revenue of $4.01M fell short of the consensus estimate of $10.74M. The company's stock price has declined significantly over the last three and twelve months, and its financial health is considered "weak performance" by InvestingPro.
Voyager Therapeutics 3Q 2026: Revenue $4.01M, EPS ($0.4) — 10-Q Summary
Voyager Therapeutics reported a decline in collaboration revenue year-over-year in Q3 2026, reaching $4.01 million, but narrowed its net loss to ($24.69 million) and improved diluted EPS to ($0.4). The company's cash runway is expected to extend into Q2 2028, supported by current cash, equivalents, and collaboration reimbursements. Business highlights include FDA clearance for VY1706 and the completion of patient visits for VY7523's Phase 1 trial.
Voyager Reports Third Quarter 2026 Financial and Operating Results
Voyager Therapeutics, Inc. reported its third quarter 2026 financial and operating results, highlighting strong momentum in its Alzheimer's disease programs, VY7523 and VY1706, with key clinical data readouts expected soon. The company also noted a reduction in year-over-year operating expenses, extending its cash runway into Q2 2028. Additionally, Voyager announced that its Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program is expected to enter clinical study in the coming months.
Voyager Therapeutics stock trades at EUR 1.71 on Thursday
Voyager Therapeutics, a biotechnology company focused on genetic medicines for neurological diseases like Alzheimer's, saw its stock trade at EUR 1.71 on Thursday, November 5, 2026. The company's pipeline and upcoming clinical calendar events, including CTAD 2026 poster presentations for its gene therapy and antibody programs, remain key points of investor focus. Voyager Therapeutics is developing treatments for various neurological conditions, often leveraging its TRACER AAV capsid discovery platform and collaborations with major pharmaceutical partners.
Voyager Therapeutics stock trades at EUR 1.61 on Tuesday
Voyager Therapeutics, a biotechnology company, will hold two Alzheimer presentations on November 16 and 17, 2026, providing a near-term event for investors. The company's stock traded at EUR 1.61 on Lang & Schwarz at 13:30 CET on Tuesday, November 3, 2026. This information offers investors a direct market reference and a key calendar item for tracking the company's gene therapy programs.
Voyager Therapeutics stock last traded at EUR 1.56 on October 31
Voyager Therapeutics stock last traded at EUR 1.56 on October 31, 2026, at Lang & Schwarz. The US biotechnology company focuses on gene therapy development, and investors are awaiting the next US trading session to see if the listing establishes a new trading level after the weekend. The article provides a snapshot of the company and its recent quote.
H.C. Wainwright Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating for Voyager Therapeutics (VYGR) with a $25.00 price target. This aligns with a Strong Buy consensus from analysts, implying a significant upside. The company recently reported quarterly revenue of $3.17 million and a GAAP net loss of $24.47 million for the quarter ending June 30.
Voyager announces CTAD posters for Voyager Therapeutics stock
Voyager Therapeutics (VYGR) announced two poster presentations for the Clinical Trials on Alzheimer's Disease (CTAD) conference, scheduled for November 16-17, 2026. The presentations will cover investigational gene therapy VY1706 and monoclonal antibody VY7523, both addressing early Alzheimer's disease. The company also detailed a leadership transition, with Robin Swartz expected to succeed Alfred W. Sandrock as CEO in Q1 2027, coinciding with initial safety data for VY1706.
Voyager Therapeutics to present Alzheimer’s gene therapy and antibody data at CTAD 2026.
Voyager Therapeutics announced it will present two poster studies at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in November 2026. The presentations will cover VY1706, a gene therapy targeting tau protein, and VY7523, an anti-tau antibody in clinical trials for early Alzheimer's. These efforts highlight Voyager's commitment to developing genetic treatments for neurological diseases.
Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
Voyager Therapeutics, Inc. announced two poster presentations for the upcoming 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Boston, November 16-19, 2026. The presentations will highlight VY1706, an investigational gene therapy designed to lower tau production, and VY7523, a clinical-stage monoclonal antibody targeting the C-terminal region of tau, both for early Alzheimer's disease. These posters will detail the first-in-human study design for VY1706 and the baseline characteristics of participants in a multiple ascending dose study for VY7523.
Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
Voyager Therapeutics announced two poster presentations at the upcoming 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in November 2026. The presentations will highlight VY1706, an investigational gene therapy designed to lower tau production, and VY7523, a clinical-stage monoclonal antibody targeting the C-terminal region of tau, both aimed at treating Alzheimer's disease. These presentations will detail the first-in-human study design for VY1706 and baseline characteristics of participants in a multiple ascending dose study for VY7523.
Voyager Therapeutics, Inc. Estimates – NASDAQ:VYGR
This page on TradingView provides financial estimates and data for Voyager Therapeutics, Inc. (NASDAQ: VYGR). Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows for comparison of actual results with average, high, and low estimates, and visualization of trends over time.
Voyager Therapeutics names Robin Swartz as president By Investing.com
Voyager Therapeutics has appointed Robin Swartz as its new President, effective immediately, with plans for her to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027. This transition is contingent on the receipt of initial acute safety data from a clinical trial for their investigational tau silencing gene therapy VY1706 for early Alzheimer’s disease. Swartz, currently Chief Business Officer and Chief Operating Officer, brings extensive experience from Genzyme Corporation and Sanofi Genzyme, while Dr. Sandrock will continue as CEO until the data release and then join the Board of Directors.
Voyager Therapeutics Appoints Robin Swartz CEO
Voyager Therapeutics has announced the appointment of Robin Swartz as its new Chief Executive Officer. This leadership change is expected to guide the company's strategic direction and advancements in its therapeutic programs. Swartz's appointment signifies a key development for Voyager Therapeutics.
Voyager Therapeutics Appoints Robin Swartz President; Expected to Succeed Alfred Sandrock as CEO in 2027
Voyager Therapeutics has appointed Robin Swartz as President, with an expectation for her to become CEO in Q1 2027, succeeding Dr. Alfred W. Sandrock, Jr. The transition is planned after the company receives initial safety data from the clinical trial of VY1706, a gene therapy for early Alzheimer's disease. Dr. Sandrock will continue to serve on Voyager's Board of Directors, ensuring continuity and strategic guidance as the company advances its neurological disease treatment pipeline.
Form 8K Voyager Therapeutics Inc For: 21 October By Investing.com
This article announces that Voyager Therapeutics Inc. filed a Form 8K on October 21, 2026. The filing is a standard disclosure for significant events that shareholders should know about. The company's stock symbol VYGR is mentioned with a -3.47% change.
Form 8K Voyager Therapeutics Inc For: 21 October By Investing.com
This article reports on the filing of a Form 8K by Voyager Therapeutics Inc. on October 21st. The filing is a standard regulatory document used by companies to announce significant events that investors should know about. The article itself provides no further details about the content of the Form 8K.
Robin Swartz Appointed President of Voyager Therapeutics with CEO Succession Planned for 2027
Voyager Therapeutics has appointed Robin Swartz as President, effective October 20, 2026, with plans for her to succeed Alfred W. Sandrock, Jr. as CEO in Q1 2027 following the release of initial safety data from the VY1706 clinical trial for early Alzheimer's Disease. Her new employment agreement includes a base salary of $625,000, a 50% annual cash bonus target, and significant equity awards. Swartz previously held roles as Chief Business Officer, Chief Operating Officer, and Principal Financial Officer at Voyager.
Voyager Therapeutics Appoints Robin Swartz President; Expected to Succeed Alfred Sandrock as CEO in 2027
Voyager Therapeutics has appointed Robin Swartz as President, effective immediately, with the expectation that she will succeed Alfred Sandrock, Jr., M.D., Ph.D., as CEO in the first quarter of 2027. Dr. Sandrock will remain CEO until initial acute safety data from the clinical trial of VY1706 is received and will then serve on Voyager's Board of Directors. This transition aims to ensure leadership continuity as the company advances its neurological disease treatment pipeline.
Voyager Therapeutics Names Robin Swartz President, Plans CEO Transition in 2027
Voyager Therapeutics has appointed Robin Swartz as President, with plans for her to succeed Alfred W. Sandrock Jr., M.D., Ph.D., as CEO in early 2027. This transition is tied to the release of initial acute safety data from VY1706, the company's gene therapy program for early Alzheimer’s disease. Swartz brings extensive experience from Genzyme Corporation and Sanofi Genzyme, and her leadership will focus on translating the company's research into clinical medicines for patients.
Voyager Therapeutics names Robin Swartz as president By Investing.com
Voyager Therapeutics, Inc. has appointed Robin Swartz as its new President, effective immediately. Swartz, currently Chief Business Officer and Chief Operating Officer, is slated to become CEO in Q1 2027, succeeding Alfred W. Sandrock, Jr., M.D., Ph.D., who will then join the Board of Directors. This transition is timed with the anticipated release of initial acute safety data from a clinical trial for the company's investigational tau silencing gene therapy, VY1706.
Voyager Therapeutics appoints Robin Swartz as president, outlines CEO succession plan
Voyager Therapeutics has appointed Robin Swartz as president, effective immediately, in addition to her current roles as chief business officer and chief operating officer. Swartz is expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in the first quarter of 2027, following initial safety data from a clinical trial. The company's board also approved a significant stock option grant and restricted stock unit award for Swartz, and Wall Street analysts maintain a bullish outlook on Voyager.
HC Wainwright keeps USD 25 target for Voyager Therapeutics stock
HC Wainwright has maintained its Buy rating and a USD 25.00 price target for Voyager Therapeutics stock, despite the company reporting a decrease in second-quarter revenue from USD 5.20 million to USD 3.17 million. The biotechnology company, which focuses on gene therapies for neurological diseases, is expected to release its next quarterly results on November 10, 2026. Voyager's valuation remains heavily dependent on its clinical pipeline progress, as it continues to be loss-making.
Voyager Therapeutics appoints Robin Swartz as president, outlines CEO succession plan
Voyager Therapeutics (NASDAQ:VYGR) has appointed Robin Swartz as president, effective immediately, and outlined a CEO succession plan. Swartz, currently chief business and operating officer, is expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in the first quarter of 2027, following initial safety data from a clinical trial for Alzheimer's disease. Analysts maintain a bullish outlook on the company, citing a strong current ratio and significant upside potential from current price levels.
Wells Fargo kept USD 10 target for Voyager Therapeutics stock
Wells Fargo has maintained its USD 10 price target and Buy rating for Voyager Therapeutics (VYGR) despite the company reporting a decrease in second-quarter revenue from USD 5.20 million to USD 3.17 million. The company's GAAP net loss narrowed, and an Alzheimer's disease clinical trial for VY1706 is expected in the second half of 2026. Voyager Therapeutics is scheduled to release its next quarterly results on November 9, 2026.
Voyager Therapeutics, Inc. (VYGR) options chain
This article provides detailed options chain data for Voyager Therapeutics, Inc. (VYGR), including information for both call and put options. It lists various contracts with their last trade date, expiry date, last price, bid, ask, change, volume, open interest, and implied volatility. The data is delayed by 15 minutes and reflects trading activity as of October 16, 2026.
Voyager Therapeutics stock trades at EUR 1.80 as revenue falls to USD 3.17 million
Voyager Therapeutics reported second-quarter revenue of USD 3.17 million, a decrease from USD 5.20 million in the prior year, with a GAAP net loss of USD 24.47 million. The company's stock was trading at EUR 1.80 on October 15, 2026, while Wells Fargo maintained a Buy rating and a USD 10.00 price target. Voyager's business remains focused on its biotechnology platform for neurological diseases, relying on development milestones and collaborations.
Voyager Therapeutics stock trades at EUR 1.80 as revenue falls to USD 3.17 million
Voyager Therapeutics (VYGR) stock is trading at EUR 1.80 as the company reported a drop in second-quarter revenue to USD 3.17 million, down from USD 5.20 million in the previous year. Despite the revenue decline, the GAAP net loss decreased to USD 24.47 million from USD 33.38 million. Wells Fargo maintained a Buy rating with a USD 10.00 price target for the biotechnology platform focused on neurological diseases.
Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Voyager Therapeutics (NASDAQ:VYGR) is identified as a high-risk investment due to its substantial cash burn and declining revenue. The company's cash runway is estimated at only 11 months, and its cash burn represents 80% of its market capitalization, raising significant concerns about its financial stability and the potential for shareholder dilution.
Wells Fargo maintains Buy on Voyager Therapeutics stock at USD 10.00
Wells Fargo has reiterated its Buy rating on Voyager Therapeutics (VYGR) stock, setting a price target of USD 10.00. This follows the company's Q2 2026 revenue of USD 3.17 million and a narrowed GAAP net loss of USD 24.47 million. Voyager Therapeutics, a clinical-stage biotechnology company focused on neurological diseases, saw its stock trading near its 52-week low.
Voyager Therapeutics stock gets Wells Fargo Buy rating and USD 10 target
Wells Fargo has maintained its Buy rating for Voyager Therapeutics (VYGR) stock and set a price target of USD 10.00, significantly above its current Nasdaq price of USD 2.46. This analyst view comes despite a weak share-price performance and a recent Q2 revenue dip to USD 3.17 million. The consensus target from 11 analysts remains even higher at USD 14.889, reflecting the high-risk, high-reward profile of this clinical-stage biotechnology company.
Dilution adjustment of Voyager Therapeutics, Inc. – HAN:VT6
This article from TradingView announces a dilution adjustment for Voyager Therapeutics, Inc. (HAN:VT6) on the Hannover Stock Exchange. The brief update indicates a change in the stock's financials due to dilution, without providing specific details on the period or value of the adjustment.
VT6 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Voyager Therapeutics, Inc. (VT6) stock, including analyst price targets and future predictions. It details the company's financial performance, such as recent earnings and revenue, and outlines when the next earnings report is expected. Additionally, it covers essential company statistics like EBITDA, employee count, and dividend policy.
ETFs Investing in Voyager Therapeutics, Inc. Stocks
This article lists various ETFs that include Voyager Therapeutics, Inc. (VT6) stocks in their portfolios. It provides a detailed table with each fund's symbol, market value, weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The ETFs cover different market segments such as biotechnology, micro-cap, small-cap, and include both passive and active management styles.
Return on equity % of Voyager Therapeutics, Inc. – HAN:VT6
This article provides the Return on Equity (%) for Voyager Therapeutics, Inc. (VT6) on the Hannover Stock Exchange. It indicates that the market was closed with no trades at the time of the report. The data presented is concise, focusing solely on this financial metric for the specified company.
Free cash flow per share of Voyager Therapeutics, Inc. – HAN:VT6
This article focuses on the free cash flow per share of Voyager Therapeutics, Inc. (HAN:VT6). It provides a general overview of the company's financials as listed on the Hannover Stock Exchange. The content is primarily a placeholder for financial data related to free cash flow per share.
Voyager Therapeutics, Inc. Revenue Breakdown – LSX:A143XJ
Voyager Therapeutics, Inc. (LSX:A143XJ) reported total revenue of 34.38 million EUR last year, a significant decrease from 77.28 million EUR in the previous year. The Genetic Medicine segment was the sole contributor to revenue, generating 34.38 million EUR. The company's entire revenue stream originated from the United States.
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics (VYGR) and maintained a $25.00 price target. This recommendation is based on the company's advancing Alzheimer's pipeline and recent financial performance, which included a quarterly revenue of $3.17 million and a GAAP net loss of $24.47 million. Voyager Therapeutics currently holds a Strong Buy analyst consensus with a $15.00 price target consensus.
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced its participation in five upcoming investor conferences in September 2026, including the Wells Fargo, Cantor Global, Morgan Stanley, Baird's, and H.C. Wainwright conferences. The company will conduct fireside chats at each event, with a webcast available for the Wells Fargo conference. Voyager Therapeutics is a biotechnology company focused on neurological diseases.
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced its participation in several upcoming investor conferences in September 2026, including the Wells Fargo, Cantor Global, Morgan Stanley, Baird's Global, and H.C. Wainwright conferences. The biotechnology company will hold fireside chats at these events, with a webcast of the Wells Fargo presentation available on its investor relations website. Voyager focuses on leveraging genetics to treat neurological diseases.
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy
H.C. Wainwright has reiterated a Buy rating for Voyager Therapeutics (NASDAQ:VYGR) and set a $25.00 price target, citing significant upside potential from its current trading price of $3.46. The firm's positive outlook is based on the company's progress with its Alzheimer's disease programs, including the anti-tau antibody VY7523 and the tau-silencing gene therapy VY1706, both on track for Q4 2026 milestones. Voyager Therapeutics also boasts a strong financial position with nearly $149 million in cash and a runway extending into 2028.
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy By Investing.com
H.C. Wainwright has reaffirmed its Buy rating and $25.00 price target for Voyager Therapeutics (NASDAQ:VYGR), citing significant upside potential from the current trading price of $3.46. The firm hosted a fireside chat with Voyager Therapeutics CEO Alfred Sandrock, discussing the company's progress on its tau programs for Alzheimer's disease, including upcoming inflection points in Q4 2026 for VY7523 and VY1706. Voyager Therapeutics reported strong financial health with nearly $149 million in cash as of Q2 2026, providing a cash runway into 2028, and recent positive preclinical data for VY1706 further support the positive outlook.